🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Pembrolizumab

    Syndax Pharmaceuticals

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  2. Pembrolizumab

    Syndax Pharmaceuticals

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  3. Pembrolizumab plus denosumab

    Zealand Pharma A/S

    Renal Cell Carcinoma, Clear Cell

    phase 2 small molecule active

    1 trial

  4. Pemetrexed

    Mereo BioPharma Group plc

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  5. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Boehringer Ingelheim

    locally advanced or metastatic NSCLC

    phase 2 small molecule active

    1 trial

  6. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, JNJ-61186372

    Fondazione Telethon ETS

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  8. Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion, REGN7075, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., LIBTAYO 350 mg concentrate for solution for infusion., Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Peptide A49 associated to melanin, Peptide A52 associated to melanin, Litenimod solution

    Pari Pharma GmbH

    glioblastoma

    phase 2 small molecule active

    1 trial

  10. Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    advanced solid tumors

    phase 2 other active

    1 trial

  11. Phase 1b: APG-115+pembrolizumab

    Ascentage Pharma Group

    Unresectable or Metastatic Melanoma or Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  12. Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  13. Phase I Study of PM534 to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advances solid tumors

    phase 2 other active

    1 trial

  14. Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  15. Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA.

    Esteve Pharmaceuticals

    Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)

    phase 2 other active

    1 trial

  16. Phenoptin

    BioMarin Pharmaceutical Australia Pty Ltd

    Tetrahydrobiopterin Deficiencies

    phase 2 small molecule completed

    1 trial

  17. Piclidenoson

    Can-Fite BioPharma

    COVID-19

    phase 2 small molecule completed

    1 trial

  18. Piclidenoson

    Can-Fite BioPharma

    Lowe Syndrome

    phase 2 small molecule active

    1 trial

  19. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  20. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  21. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  22. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  23. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Intermittent Explosive Disorder

    phase 2 small molecule active

    1 trial

  24. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources